Calcaneal Chondroblastoma with Pathologic Fracture and Recurrence

Dutt, Laksha; Schade, Valerie L.; Manoso, Mark W.

doi:10.1053/j.jfas.2014.12.006

Cited by 13 publications

(18 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It usually affects the epiphyses or apophyses of long bones such as humerus, femur and tibia. Less common location affected by chondroblastoma including patella, calcaneus, acetabulum and even spine, also had been reported in literature [9][10][11].It seems that chondroblastoma occurs more frequently in males than in females, in a ratio of 2.3 to 1 [2,12]. In this group of patients, the mean age of onset was 13 years old with a male to female ratio of 1.5:1, and also the proximal humerus was the mostly involved location, which all coincided with most previous studies.…”

Section: Discussionmentioning

confidence: 75%

10 Years Follow up of Chondroblastoma Treated with Intralesional Curettage: A Retrospective Study

Yang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction: Chondroblastoma is a rare benign tumor mainly occurred in epiphyses and apophyses of long bones, and usually affects the young people. The primary treatment for chondroblastoma is intralesional curettage. The aim of this study was to evaluate the clinical and radiologic results of patients suffering chondroblastoma treated with intralesional curettage, electrocauterization of the cavity and bone grafting. Patients and Methods: From January 2000 to January 2010, 15 patients with chondroblastoma were treated with intralesional curettage and electrocauterization of the cavity, among which14 patients received bone grafting. After operation, patients were immobilized with splint for 4 weeks and followed up for at least 10 years. The recurrence was examined by clinical manifestation and X ray. The clinical outcome included complications and the Musculoskeletal Tumor Society Score (MSTS).Results: Totally, 15 patients with chondroblastoma were enrolled in our study, including 9 males and 6 females, with a mean age of 13 years old (range from 8 to 21 years). The most common chief compliant were pain and limited joint motion, others including local swelling and increased skin temperature. The mean duration of symptom was 5 months (range from 2-14 months). Tumors mostly affected the proximal humerus (7/15), distal femur (4/15), proximal femur (1/15), proximal tibia (2/15) and femoral head (1/15). Eight patients were undiagnosed or misdiagnosed before operation, only 7 patients with a consideration of chondroblastoma. With a mean follow up of 12years (range from 10-16 years) , two patients had complications of upper limb shortening and1 patient suffered re-operation due to tumor recurrence. The mean postoperative MSTS score was 28.1 (range, 24 to 30) points, which was significantly higher than the preoperative score of 17.6 (range, 12 to 21) points.Conclusion: Thorough curettage with electrocauterization and bone grafting has a good functional outcome in the treatment of chondroblastoma, but still has a low risk of recurrence and complications.Level of Evidence: Level IV, retrospective case series.

show abstract

Section: Discussionmentioning

confidence: 75%

10 Years Follow up of Chondroblastoma Treated with Intralesional Curettage: A Retrospective Study

Yang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…It mostly affects the epiphyses or apophyses of long bones such as humerus, femur and tibia. Less common locations including patella, calcaneus, acetabulum and spine, also had been reported in literature [9][10][11].It seems that chondroblastoma occurs more frequently in males than in females, with a ratio of 2.3 to 1 in literature [2,12]. In our study of chondroblastoma , the mean age of onset was 13 years old with a male to female ratio of 1.5:1, and also the proximal humerus was the mostly involved location, which all coincided with most previous studies.…”

Section: Discussionmentioning

confidence: 81%

Outcome of Chondroblastoma Treated With Intralesional Curettage and Autogenous Iliac Bone Graft: A Retrospective Study

Yang¹,

Yang²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundChondroblastoma is a rare benign tumor mainly occurred in epiphyses and apophyses of long bones, and usually affects the young people. The primary treatment for chondroblastoma is intralesional curettage. The aim of this study was to evaluate the clinical result of patients suffering chondroblastoma treated with intralesional curettage, electrocauterization of the cavity and autogenous iliac bone grafting. MethodsFrom January 2000 to January 2010, 15 patients with chondroblastoma were treated with intralesional curettage and electrocauterization of the cavity, and 14 of them received autogenous iliac bone grafting. After operation, patients were immobilized with splint for 4 weeks and followed up for at least 10 years. The recurrence was examined by clinical manifestation and X ray. The clinical outcome included complications and the Musculoskeletal Tumor Society Score (MSTS).ResultsTotally, 15 patients with chondroblastoma were enrolled in our study, including 9 males and 6 females, with a mean age of 13 years old (range from 8 to 21 years). The most common chief compliant were pain and limited joint motion, others including local swelling and increased skin temperature. The mean duration of symptom was 5 months (range from 2-14 months). Tumors mostly affected the proximal humerus (7/15), distal femur (4/15), proximal femur (1/15), proximal tibia (2/15) and femoral head (1/15). With a mean follow up of 12years (range from 10-16 years) , two patients had complications of upper limb shortening and one patient suffered re-operation due to tumor recurrence. The mean postoperative MSTS was 28.1 (range, 24 to 30) points, which was significantly higher than the preoperative score of 17.6 (range, 12 to 21) points.ConclusionsThorough curettage with electrocauterization and autogenous iliac bone grafting has good functional outcomes in the treatment of chondroblastoma, but still has a low risk of recurrence and complications.Level of EvidenceLevel IV, retrospective case series.

show abstract

“…A physical examination mostly involves oedema and painful palpation of the heel in addition to joint dysfunction of the ankle ( 47 ). All routine laboratory tests produce results that are within normal ranges ( 48 ).…”

Section: Benign Calcaneal Tumour Typesmentioning

confidence: 99%

Primary tumours of the calcaneus (Review)

et al. 2018

View full text Add to dashboard Cite

The calcaneus is a rare location for the occurrence and development of primary tumour types. Clinicians are unfamiliar with calcaneal tumour types, which may result in a delay in diagnosis or a missed diagnosis, resulting in unnecessary morbidity and amputation. Heel pain and localized swelling of the ankle are the most common symptoms. X-ray is the first choice for a tentative diagnosis of a calcaneal tumour. The final diagnosis depends on a histological examination. The treatment of calcaneal tumour types varies depending on the Enneking system. The majority of patients with benign tumours heal, except for a few with a palindromia. For malignant tumours, the prognosis is comparatively poor, resulting in disability and a high rate of metastasis. This review describes the spectrum of calcaneal tumour types and specifically illustrates the epidemiology, symptomatology, imagology, histopathology and treatment options that may facilitate diagnosis and improve prognosis.

show abstract

Calcaneal Chondroblastoma with Pathologic Fracture and Recurrence

Cited by 13 publications

References 58 publications

10 Years Follow up of Chondroblastoma Treated with Intralesional Curettage: A Retrospective Study

10 Years Follow up of Chondroblastoma Treated with Intralesional Curettage: A Retrospective Study

Outcome of Chondroblastoma Treated With Intralesional Curettage and Autogenous Iliac Bone Graft: A Retrospective Study

Primary tumours of the calcaneus (Review)

Contact Info

Product

Resources

About